¨A síndrome de Lennox-Gastaut (SLG) é uma das formas mais graves de epilepsia na infância devido à alta frequência de convulsões, resistência aos medicamentos e frequência associativa com comprometimento cognitivo. Se inicia comumente antes da idade de 5 anos, mais comum no sexo maisculino e se caracteriza por crises tônicas-axiais, atônicas e de ausência atípica. O EEG caracteriza-se por um padrão de ponta e onda frontocentral dominante lento (< 3 Hz) e os pacientes apresentam deficiência mental. As convulsões são de difícil controle e é comum um status epilepticus associado a torpor, espasmos e alterações do tônus. Em torno de 60% dos pacientes têm uma causa subjacente clara de encefalopatia (sintomática). Os demais casos são criptogênicos ou idiopáticos. Muitos medicamentos inicialmente reduzem a frequência de conulsões, mas, com o tempo, perdem sua eficácia. A Liga Internacional contra a Epilepsia (ILAE) enfatizou a importância da detecção precoce de crianças que são candidatas a procedimentos cirúrgicos no tratamento da SLG e recomendou o encaminhamento imediato para centros cirúrgicos especializados. Existem três opções na abordagem cirúrgica da epilepsia em crianças com SLG: ressecl~çao cirúrgica, calosotomia e estimulalçao do nervo vago.¨
■ Lennox-Gastaut syndrome in mitochondrial disease
Soonie Lee, Min-Seong Baek, Young-Mock Lee
Yonsei Med J. 2019 Jan 1; 60(1): 106–114
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298891/
■ Burden of illness in patients with possible Lennox-Gastaut syndrome: a retrospective claims-based study
N L Reaven, S E Funk, G D Montouris et al
Epilepsy & Behavior 2018, vol 88: p66-67
https://www.epilepsybehavior.com/article/S1525-5050(18)30545-6/fulltext
■ The refractory epilepsy screening for Lennox-Gastaut syndrome (REST-LGS)
J E Piña-Garza, D Boyce, D M Tworek et al
Epilepsy & Behavior 2018, vol 90: p148-153
https://www.epilepsybehavior.com/article/S1525-5050(18)30566-3/fulltext
■ Optimizing clobazan treatment in patients with Lennox-Gastaut syndrome
J Isojarvi, B E Gidal, S Chung, R T Wechsler
Epilepsy & Behavior 2018, vol 78: p14—154
https://www.epilepsybehavior.com/article/S1525-5050(17)30721-7/fulltext
■ Síndrome de Lennox Gastaut: aproximación diagnóstica y avances terapéuticos: Fármacos antiepilépticos, Canabidiol y otras alternativas.
Herrera, Manuel L and Burneo, Jorge G
Rev Neuropsiquiatr, Abr 2018, vol.81, no.2, p.82-
http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S0034-85972018000200005&lng=es&nrm=iso
■ Lennox-Gastaut syndrome and palliative surgical treatment – bibliographic review
B C Ribeiro, G Estevam, P H P de Aguiar, S Simis
Rev Chil Neurocirurgia 2018, vol 44: 83-88
http://www.neurocirugiachile.org/pdfrevista/v44_n1_2018/decastro_p83_v44n1_2018.pdf
■ Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations
- Helen Cross, Stéphane Auvin, Mercè Falip et al
Front Neurol. 2017; 8: 505
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649136/
■ Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends challenges and future directions
Adam P Ostendorf, Yu-Tze Ng
Neuropsychiatr Dis Treat. 2017; 13: 1131–1140
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404809/
■ Ophthalmologic features of Lennox-Gastaut syndrome
Bo Hee Kim, Young Suk Yu, Seong-Joon Kim
Korean J Ophthalmol. 2017 Jun; 31(3): 263–26
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469930/
■ Assessment of treatment patterns and healthcare cost associated with probable Lennox-Gastaut syndrome
J E Piña-Garza, G D Montouris, F Vekeman et al
Epilepsy & Behaviour 2017, vol 73: 46-50
http://www.epilepsybehavior.com/article/S1525-5050(17)30286-X/fulltext
■ Electroencephalography network effects of corpus callosotomy in patients with Lennox-Gastaut syndrome
Jun-Ge Liang, Dongpyo Lee, Song Ee Youn, Heung Dong Kim, Nam-Young Kim
Front Neurol. 2017; 8: 456
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591410/
Recent developments in the genetics of childhood epileptic encephalopathies: impact in clinical practice
■ Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide
Rob McMurray, Pasquale Striano
Neurol Ther. 2016 Jun; 5(1): 35–43
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919131/
■ Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazan in Lennox-Gastaut syndrome
Michele A Faulkner
Ther Clin Risk Manag. 2015; 11: 905–914
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467745/
■ Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox-Gastaut syndrome
Sudha Kilaru Kessler, Ann McCarthy, Avital Cnaan, Dennis J. Dlugos
Epilepsy Res. 2015 May; 112: 18–2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805421/
■ Síndrome de Lennox-Gastaut, una revisión actualizada
P David, V Garcia, S Meneses
Revista Chilena de Epilepsia 2014, Año 14 (3)
■ Conceptualizing Lennox-Gastaut syndrome as a secondary network epilepsy
John S. Archer, Aaron E. L. Warren, Graeme D. Jackson, David F. Abbott
Front Neurol. 2014; 5: 225.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214194/
■ Experience in the use of clobazan in the treatment of Lennox-Gastaut syndrome
Gabriela Purcarin, Yu-Tze Ng
Ther Adv Neurol Disord. 2014 May; 7(3): 169–176
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994921/
■ Stable dosages of clobazan for Lennox-Gastaut syndrome are associated with sustained dro-seizure and total-seizure improvements over 3 years
Joan A Conry, Yu-Tze Ng, Lydia Kernitsky et al
on-behalf-of the OV-1004 Study Investigators
Epilepsia. 2014 Apr; 55(4): 558–56
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303987/
■ Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome
K M Clements, M Skornicki, A K O´Sullivan
Epilepsy & Behavior 2013, vol 29: p184-189
https://www.epilepsybehavior.com/article/S1525-5050(13)00334-X/fulltext
■ Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox-Gastaut syndrome: a meta-analysis
Guido Lancman, Michael Virk, Huibo Shao et al
Seizure. 2013 Jan; 22(1): 3–8.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655762/
■ Síndrome de Lennox-Gastaut
G ZAldívar-Pascua, G Dávila-Gutiérrez
Acta Pediátrica de México 2011, vol 32: 75-76
https://www.redalyc.org/pdf/4236/423640327012.pdf
■ Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamid
Jessica Gresham, Lea S Eiland, Allison M Chung
Neuropsychiatr Dis Treat. 2010; 6: 639–645.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951747/
■ Síndrome de Lennox-Gastaut
L B Maldonado, A J M Avellan
El Residente 2009, vol IV (2)
http://www.medigraphic.com/pdfs/residente/rr-2009/rr092e.pdf
■ Treatment of Lennox-Gastaut syndrome: overview and recent findings
Kenou van Rijckevorsel
Neuropsychiatr Dis Treat. 2008 Dec; 4(6): 1001–1019.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646636/
■ Lennox-Gastaut syndrome, review of the literature and a case report
T A Saleh, L Stephen
Head Face Med 2008, vol 4: 9
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483705/
■ Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)
Gerhard Kluger, Bettina Bauer
Neuropsychiatr Dis Treat. 2007 Feb; 3(1): 3–11
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654531/
by Dr Paulo Fernando Leite
Médico Cooperado Unimed BH – CRMMG: 7026
Cardiologia – Centro Médico Unimed BH
Belo Horizonte/Minas Gerais/Brasil
Email: pfleite1873@gmail.com